Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: @NEJM
🥸 Vutrisiran is promising: congratulations to authors!
👇👇👇
🥸 1/ ATTR-CM is a progressive, fatal disease. It occurs due to misfolded transthyretin proteins depositing in the heart muscle, causing infiltrative cardiomyopathy. Vutrisiran, an RNA interference agent, offers new therapy by targeting the production of hepatic transthyretin.
🥸 2/ The HELIOS-B trial evaluated vutrisiran in 655 patients with ATTR-CM. Patients were randomized 1:1 to receive vutrisiran (25 mg subcutaneously every 12 weeks) or placebo for up to 36 months.
🥸 Nice review in JAMA on AF by @darae_ko and team; congratulations.
😱 20-points here
👇👇👇
🥸 1️⃣ Atrial fibrillation (AF) affects ~10.55 million US adults. It increases the risk of stroke, heart failure (HF), myocardial infarction, chronic kidney disease, dementia, and death.
😱Managing AF effectively is critical to improving CV outcomes.
🥸 2️⃣ AF symptoms range from palpitations, shortness of breath, chest pain, presyncope, and fatigue to being completely asymptomatic.
😱About 10-40% of people with AF don’t notice symptoms, which makes screening and incidental detection critical.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM
🥸The SUMMIT trial - @AHAScience
😱 Summary
👇👇👇
🥸 1️⃣ Obesity drives heart failure with preserved ejection fraction (HFpEF) through systemic inflammation and visceral adiposity. Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers weight loss and potential cardiovascular benefits.
🥸 2️⃣ The SUMMIT trial evaluated 731 HFpEF patients with obesity (BMI ≥30), randomized to tirzepatide or placebo for 52 weeks. Primary outcomes were a composite of cardiovascular death or worsening HF events and improvement in health status (KCCQ-CSS).
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation: @NEJM
🥸The OPTION trial: @AHAScience
😱 Summary
👇👇👇👇
🥸 1️⃣ Oral anticoagulation is standard after atrial fibrillation (AF) ablation for stroke prevention but comes with bleeding risks and patient burdens. Left atrial appendage closure (LAAC) offers an alternative, but data comparing these strategies post-ablation have been limited.
🥸 2️⃣ The OPTION trial evaluated 1,600 patients post-AF ablation, randomized to LAAC (device group) or oral anticoagulation (anticoagulation group). Patients had a CHA2DS2-VASc score ≥2 (men) or ≥3 (women), indicating moderate-to-high stroke risk.